{"id":16925,"date":"2018-01-02T16:34:17","date_gmt":"2018-01-02T15:34:17","guid":{"rendered":"http:\/\/mabdesign.fr\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/"},"modified":"2018-01-02T16:34:17","modified_gmt":"2018-01-02T15:34:17","slug":"clean-cells-a-partner-in-an-innovative-project-hybridadcc","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/","title":{"rendered":"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d"},"content":{"rendered":"

Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d<\/span><\/span><\/strong><\/p>\n

\n

Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d.<\/p>\n

This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology. The goal is to identify new antibodies and new therapeutic targets in the huge mouse antibody reservoir before moving these hints forward the human therapeutic field.<\/p>\n<\/div>\n

To know more<\/a><\/span><\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-16925","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members"],"yoast_head":"\nClean Cells, a partner in an innovative project: \u201cHybridADCC\u201d - MabDesign<\/title>\n<meta name=\"description\" content=\"Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d. This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d. This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-02T15:34:17+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d\",\"datePublished\":\"2018-01-02T15:34:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\"},\"wordCount\":132,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\",\"name\":\"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2018-01-02T15:34:17+00:00\",\"description\":\"Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d. This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d - MabDesign","description":"Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d. This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/","og_locale":"en_US","og_type":"article","og_title":"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d - MabDesign","og_description":"Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d. This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology.","og_url":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/","og_site_name":"MabDesign","article_published_time":"2018-01-02T15:34:17+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d","datePublished":"2018-01-02T15:34:17+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/"},"wordCount":132,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/","url":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/","name":"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2018-01-02T15:34:17+00:00","description":"Clean Cells and its partners \u2013 OSE Immunotherapeutics SA, INSERM UMR1232\/CNRSERL6001, the MicroPiCell platform\u2013 have been granted with a \u20ac2,4M funding from the Fonds Unique Interminist\u00e9riel (FUI \u2013 cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: \u201cHybridADCC\u201d. This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human\/mouse technology.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/clean-cells-a-partner-in-an-innovative-project-hybridadcc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Clean Cells, a partner in an innovative project: \u201cHybridADCC\u201d"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16925"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16925\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}